News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated
